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Context: Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully 
elucidated and different dosing regimens have never been compared head to head. 
Objective: The objective of the study was to investigate the relationship between mitotane dose and plasma concentration comparing two 
dosing regimens. 
Design/Setting: This was a prospective, open-label, multicenter trial of a predefined duration of 12 weeks. 
Patients/Interventions: Forty mitotane-naïve patients with metastatic adrenocortical carcinoma were assigned to a predefined low- or high-
dose regimen by the local investigator. Thirty-two patients could be evaluated in detail. 
Main Outcome Measure: The difference in median mitotane plasma levels between both treatment groups was measured. 
Results: Despite a difference in mean cumulative dose (440 _ 142 g vs 272 _ 121 g), median maximum plasma levels were not significantly 
different between the two groups [high dose 14.3 mg/L (range 6.3–29.7, n _ 20) vs 11.3 mg/L (range 5.5–20.0, n _ 12), P _ .235]. Ten of 20 
patients onthe high-dose regimen reached plasma concentrations of 14 mg/L or greater after 46 days (range 18–81 d) compared with 4 of 12 
patients on the low-dose regimen after 55 days (range 46–74 d, P _ .286). All patients who reached 14 mg/L at 12 weeks displayed a level of 
4.1 mg/L or greater on day 33 (100% sensitivity). There were no significant differences in frequency and severity of adverse events. Among 
patients not receiving concomitant chemotherapy mitotane exposure was higher in the high-dose group: 1013 _ 494 mg/L _ d vs 555 _ 168 
mg/L _ d (P _ .080).  
Conclusions: The high-dose starting regimen resulted in neither significantly different mitotane levels nor a different rate of adverse events, 
but concomitant chemotherapy influenced these results. Thus, for mitotane monotherapy the high-dose approach is favorable, whereas for 
combination therapy a lower dose seems reasonable.  
 
 
  
Current medical treatment of advanced adrenocortical 
carcinoma (ACC) is based on mitotane given either 
as monotherapy or combined with cytotoxic chemotherapy 
(1, 2). Mitotane is registered in the United States since 
1970 for the treatment of advanced ACC and was in 2004 
also authorized by the European Medicines Agency. Despite 
this long history of use, its mechanism of action and 
pharmacokinetic properties are not fully elucidated (3). 
There is evidence of a correlation between mitotane 
plasma levels and antineoplastic efficacy. Studies have 
demonstrated an objective response rate of 55%–66% in 
patients whose plasma levels were above 14 mg/L, 
whereas lower levels were associated with lack of efficacy 
(4–6). The concept that mitotane levels predict treatment 
response has been confirmed in a large multicenter study 
(7). Accordingly, monitoring plasma levels is considered 
to be as standard of care. 
Information on mitotane pharmacokinetics primarily 
originates from a study performed in 1960 (8). It appears 
that 35%–40% of the drug is absorbed from the gastrointestinal 
tract and is stored primarily in adipose tissues. 
This may explain the time lag of 4 weeks to several months 
necessary for reaching target plasma levels (9 –12). Thus, 
higher starting doses have been proposed to earlier reach 
the therapeutic window (13). In addition, some groups 
suggested that mitotane plasma level after 2–4 weeks 
might predict whether the patient reaches the target level 
within a short time, justifying monotherapy in these patients 
(2, 13). 
Metabolism of mitotane results in the formation of two 
metabolites, 2,4-dichlorodiphenyl acetic acid (DDA) and 
1,1-(o,p_-dichlorodiphenyl)-2,2-dichloroethene (DDE), 
of whichDDAhas been identified as the major circulating 
and excreted metabolite (14). A recent retrospective study 
in a group of 91 patients with ACC demonstrated that 
DDA plasma levels greater than 92 mg/L may be associated 
with tumor response (7). 
Tolerability is a matter of concern because adverse effects 
occur frequently and are also related in part to drug 
levels. However, the number of patients who discontinue 
therapy can be minimized by regular counseling about the 
management of adverse effects, careful adjustment of hormone 
replacement therapies, and tailoring of mitotane 
dosage based on plasma levels and side effects (15). 
The recently completed first randomized trial in advanced 
ACC [First International Randomized Trial in 
Locally Advanced and Metastatic Adrenocortical Carcinoma 
Treatment (FIRM-ACT)] compared two chemotherapy 
regimens and established etoposide, doxorubicin, 
and cisplatin (EDP) plus mitotane as first-line cytotoxic 
chemotherapy for patients with ACC (16). The present 
study was nested within FIRM-ACT with the aim to better 
understand the relationship between mitotane dose (daily 
and cumulative) and plasma concentrations by comparing 
two predefined starting regimens (high dose and low 
dose). Secondary objectives were to evaluate the safety of 
mitotane and its impact on various hormonal parameters. 
Time to reach a mitotane plasma level of 14 mg/L was 
determined as a post hoc end point. In addition, we examined 
whether mitotane levels assessed early in therapy 
were predictive for reaching 14 mg/L within 12 weeks. 
This is the first prospective multicenter study aimed at 
improving knowledge on the pharmacokinetic properties 
of mitotane. 
 
Materials and Methods 
Patients 
The main eligibility criteria were histologically confirmed locally 
advanced or metastatic adrenocortical carcinoma not amenable 
to radical surgical resection, radiologically monitorable 
disease, Eastern Cooperative Oncology Group (ECOG) performance 
status 0–2, life expectancy longer than 3 months, age 18 
years or older, adequate hematological and biochemical function, 
effective contraception, written informed consent, and the 
ability to comply with study procedures. Exclusion criteria were 
previous treatment with mitotane, cytotoxic chemotherapy or 
experimental drugs for ACC, history of prior malignancy, renal 
or hepatic insufficiency, pregnancy, breast-feeding, presence of 
active infection, decompensated heart failure, myocardial infarction, 
or revascularization procedure in the last 6 months. The 
protocol was approved by the institutional ethics committees 
and all patients gave informed consent. 
Study design and treatment 
The study was an international prospective, open-label, multicenter 
study. Treatment with mitotane was initiated at least 2 
weeks prior to the start of cytotoxic chemotherapy. Assignment 
to one of two dosing regimens was at the discretion of the local 
investigator without detailed inclusion criteria. A detailed summary 
of both regimens is provided in Table 1. Mitotane was 
taken orally in three daily doses with food. The predefined study 
duration for each patient was 12 weeks. 
Measurement of mitotane and metabolites 
Mitotane plasma level was assessed weekly during the first 8 
weeks and then at weeks 10 and 12. Sampling was performed in 
the morning at least 12 hours after the last dose. Quantitative 
analyses of mitotane,DDA,andDDEwere performed by Parexel 
(Bloemfontein, South Africa) using HPLC (17). 
Safety assessments 
Adverse events (AEs) were monitored throughout the study 
and assessed with the use of the National Cancer Institute Common 
Terminology Criteria (NCI-CTC) for Adverse Events version 
2.0. Dosing of iv chemotherapy in case of hematological, 
renal, and neurological toxicity was done according to the study 
protocol. Mitotane dose was adjusted in case of grade 3/4 gastrointestinal 
AE and/or grade 2–4 central nervous system (CNS) 
AE (Table 1). In case of greater than grade 3 nonhematological 
toxicity (except alopecia) both mitotane and chemotherapy were 
temporarily discontinued. Liver enzymes [serum glutamic pyruvic 
transaminase, serum glutamic oxaloacetic transaminase, 
_-glutamyltransferase (GGT)] were analyzed at baseline, week 4, 
and week 12. 
Endocrine work-up 
All hormone analyses were performed using validated assay 
methods by Bicêtre Hospital (Department of Endocrinology, 
Paris, France). TSH, free FT3 (FT3), free T4 (FT4), T4-binding 
globulin (TBG), and SHBG (or sex hormone binding protein) 
were measured at baseline and at weeks 4 and 12. Total and free 
T, FSH, andLHwere measured before treatment and at week 12. 
Statistical analysis 
Only limited data were available on inter- and intrasubject 
variability of mitotane pharmacokinetics, precluding a classical 
sample size calculation. It was estimated that it would be necessary 
to recruit eight patients per subgroup (high/low dose, 
EDP/streptozotocin chemotherapy) to investigate differences between 
both dosing regimens and to evaluate safety. Assuming 
some dropouts, the study aimed at an inclusion of 40 patients. 
The following pharmacokinetic parameters were calculated per 
protocol: plasma concentration before morning dose; highest 
plasma concentration observed (Cmax); time to reach Cmax; and 
area under the concentration-time curve (AUC0-t). The post hoc 
end point median time to reach a mitotane plasma level of 14 
mg/L was measured in days among patients in both regimens. 
The predictive value of early mitotane levels was examined using 
receiver-operating characteristic analyses. Data on thyroid and 
sex hormones are displayed according to mitotane plasma level. 
Adverse events are displayed according to severity and dosing 
regimen. Results are expressed as mean _ SD or median and 
range as indicated. Data were analyzed by the Biostatistics Unit 
of BIOTRIAL. 
 
Results 
Patient characteristics 
Forty patients were enrolled in the study between 2004 
and 2009. There were 19 men (48%) and 21 women 
(52%), mean age was 51 years, and mean body mass index 
was 25.3 kg/m2. Table 2 displays demographic data according 
to the subgroups. Because all participants had to 
sign informed consent for the FIRM-ACT study at inclusion, 
the intention was to administer chemotherapy to all 
participants. However, 17 patients were not randomized 
in FIRM-ACT and did not receive chemotherapy during 
this substudy due to indolent disease (n _ 8), rapid progression 
of disease (n _ 3), patient’s refusal (n _ 2), early 
death (n _ 2), revision of tumor staging (n _ 1), or violation 
of inclusion criteria (n _ 1). 
As stated in the study protocol, all 40 patients were 
included in safety analyses. Eight patients were excluded 
from the per-protocol analysis of pharmacokinetics: three 
patients died after 19, 21, and 24 days due to disease pro- 
gression (n _ 2) and pulmonary embolism (PE) (n _ 1), 
respectively; in two patients protocol deviations resulted 
in missing at least three consecutive pharmacokinetic measurements, 
two patients did not respect the inclusion criteria 
and were rapidly excluded (after 4 and 6 d of treatment, 
respectively), and one patient refused to continue 
mitotane after 14 days (Figure 1). 
From the remaining 32 patients, four patients were excluded 
from analyses concerning cumulative doses because 
they discontinued the study before the projected end 
point at week 12: one patient died after 39 days, one patient 
had severe CNS disorders (d 68), and two patients 
failed to comply with the protocol (d 65 and 71). 
Mitotane cumulative dosage and plasma 
concentrations 
Mean cumulative doses over the treatment period were 
substantially higher in the high-dose group (440 _ 142 g) 
compared with the low-dose group (272 _ 121 g). Ten of 
20 patients on the high-dose regimen (50%) reached 
plasma concentrations of 14 mg/L or greater compared 
with 4 of 12 patients on the low-dose regimen (33%). In 
the high-dose group, this level was reached after a median 
of 46 days (range 18–81 d) compared with 55 days (range 
46–74 d, P _ .286) in the low-dose group. Receiver-operating 
characteristic curves identified a plasma level of 
6.0 mg/L on day 33 as the best compromise between sen- 
sitivity (86%) and specificity (61%) to predict attainment 
of the therapeutic level within 12 weeks. All patients who 
reached 14 mg/L displayed a level of 4.1 mg/L or greater 
on day 33 (100% sensitivity). 
Mean cumulative dose needed to reach 14 mg/L was 
291 _ 126 g (high dose) vs 137 _ 39 g (low dose, P _ 
.020). MedianCmax was 14.3 mg/L (range 6.3–29.7 mg/L) 
in the high-dose group (n _ 20) and 11.3 mg/L (range 
5.5–20.0 mg/L) in the low-dose group (n_12, P_.235). 
It should be noted that mitotane plasma levels in most 
patients were still rising and no plateau was reached 
within 12 weeks (Figure 2A). At the last visit in week 12, 
the median plasma level was 14.2 mg/L (range 2.1–29.7 
mg/L) in the high-dose group and 10.6 mg/L (range 2.3– 
18.1 mg/L) in the low-dose group (P _ .120). Mitotane 
exposure was higher in the high-dose group but did not 
reach statistical significance (AUC0–12 weeks 790 _ 444 
mg/L _ d vs 543 _ 215 mg/L _ d, P _ .171). 
Metabolites of mitotane 
Median DDA Cmax was 99.7 
_g/mL (range 23.2–185.0_g/mL) in 
the high-dose group (n _ 20) and 
88.0 _g/mL (range 35.4–102.0 _g/ 
mL) in the low-dose group (n _ 12, 
Figure 2B). 
Twelve of 20 high-dose patients 
(60%) reached DDA levels above 92 
mg/L on at least one occasion compared 
with 3 of 12 in the low-dose 
regimen (25%) (P _ .076). Median 
time to reach aDDAlevel of 92 mg/L 
was 11 days after the start of treatment 
(high dose, n _ 12) vs 46 days 
(low dose, n _ 3). Of 15 patients 
reaching DDA plasma levels greater 
than 92 mg/L, nine (60%) also had 
mitotane plasma levels above 14 
mg/L, eight ofwhomwere treated according 
to the high-dose schedule. 
Plasma concentrations of DDE 
were below the limit of quantification 
on most occasions. Nine patients 
on the high-dose regimen and 
two on the low-dose regimen presented 
measurable DDE values. In 
week 12, mean DDE plasma concentration 
among the high-dose patients 
was 0.67 _ 0.17 mg/L and 0.68 _ 
0.15 mg/L in the low-dose group. 
Effect of concomitant cytotoxic 
chemotherapy on mitotane 
plasma level 
The mean cumulative mitotane dose in patients receiving 
chemotherapy in addition to mitotane (n _ 19) was 
comparable with the dose administered to 13 patientswho 
did not receive cytotoxic chemotherapy (358 _ 143 g vs 
389_132 g; P_.574). Within the chemotherapy group, 
patients on the high-dose regimen had a median plasma 
level in week 12 of 9.2 mg/L (range 2.1–27.1 mg/L, n _ 
12), and four patients reached plasma levels of 14 mg/L or 
higher. The median plasma level was not significantly different 
from patients on the low-dose regimen [10.8 mg/L 
(range 2.3–18.1 mg/L), n _ 7], of whom two patients 
reached the threshold of 14 mg/L. 
Among patients not receiving chemotherapy, higher 
median plasma levels were observed in the high-dose 
group: 18.3 mg/L (range 0.3–29.7 mg/L, n_8) compared 
with 10.3 mg/L (range 7.4–15.7 mg/L, n _ 5) in the lowdose 
group, but results were not statistically significant. 
Figure 2. Median mitotane (A) and DDA (B) plasma concentration throughout the study in both 
dosing regimens. 
The observation was reflected by a largerAUC0–12 in this subgroup: 
1013_494 mg/L _dvs555_168 mg/L _ d (P_.081). 
Six of eight patients from the high-dose group reached 
a plasma level of 14 mg/L; in the low-dose group, this was 
reached by two of five patients. 
Safety and toxicity 
All 40 patients were evaluated for safety. A total of 200 
AEs was reported, most of them were NCI-CTC grade 1 
or 2 (n _ 166, Table 3). The remaining AEs were grade 3 
(n_28) or grade 4 (n_6). The rate of AE per patient was 
similar in both groups (5.0 vs 5.2 AE/patient). 
Almost half of all AEs (n_96, 48%) were related to the 
gastrointestinal system, mostly nausea (n _ 30), diarrhea 
(n _ 23), and vomiting (n _ 15). One grade 4 event was 
reported: gastrointestinal bleeding. The rate of gastrointestinal 
AEs per patient was slightly higher in the low-dose 
group (2.8 AE/patient vs 2.1 AE/patient). 
There were eighteen AEs (9%) related to general disorders. 
General discomfort NCI-CTC grade 1 (n _ 6), 
asthenia (n _ 4), and fatigue (n _ 4) were most common 
events in this category. Most events were reported among 
patients on the high-dose regimen (n _ 16). 
Fourteen AEs were related to metabolism and nutrition 
(7%); 10 occurred in the high-dose group. There were two 
grade 4 AEs: these were episodes of hypomagnesaemia 
and hypokalemia, both probably related to concomitant 
cytotoxic treatment with EDP. There were four events in 
the low-dose group, all hypercholesterolemia grade 2 
or less. 
Eighteen events were related to disorders of the nervous 
system (9%). Vertigo (n _ 6) and dizziness (n _ 5) were 
mostcommon.Regarding psychiatric AEs, there were four 
reports of anxiety attacks and two reports of insomnia. 
Depression and hallucination were both reported once. 
Changes in hepatic enzymes were seen frequently. After 
12 weeks, the mean level of GGT was 361 _ 248 IU/L 
compared with 123 _ 191 IU/L at baseline. All patients 
had elevated GGT levels, with 89 IU/L being the lowest 
level. The mean level of serum glutamic oxaloacetic 
transaminase in week 12 was 46_24 IU/L, and the mean 
serum glutamic pyruvic transaminase was 52 _ 36 IU/L. 
Four patients died during the study. Two patients died 
due to disease progression, one patient died after PE, and 
one patient died after severe cardiac failure, but these 
events were not considered drug related. 
Hormonal parameters 
Mean TSH did not change significantly over the course 
of this 12-week study, both in patients with high and low 
mitotane plasma levels (Table 4). In patients who did not 
reach a mitotane level of 14 mg/L (n_14), mean FT4 level 
in week 12 was 5.7 _ 4.5 pmol/L lower compared with 
baseline. The decrease was greater in patients with mitotane 
plasma levels greater than 14 mg/L: 7.7_3.2 pmol/L 
(n _ 11). Three patients already were on thyroid replacement 
therapy prior to the study. In three other patients, 
this was started during the study: two in the high-dose 
regimen and one in the low-dose regimen. 
Mean TBG levels increased during the trial. Among 
patients who were evaluated in week 12, a mean increase 
of 5.1 _ 8.8 IU/mL was observed in those with mitotane 
levels below 14 mg/L (n _ 14). A mean increase of 7.2 _ 
7.5 IU/mL was seen in patients with mitotane levels greater 
than 14 mg/L (n _ 11). 
Analysis of sex hormones in males evaluated at week 12 
showed a mean increase in LH level in week 12 of 4.5 _ 
3.8 IU/L for those with mitotane levels below 14 mg/L (n_ 
5). In patients with mitotane levels greater than 14 mg/L, 
the mean increase was 5.7 _ 3.8 IU/L (n _ 6). 
The mean level of free T in males tended to decrease 
during the study, whereas the mean level of totalTin week 
12 was not different from baseline. Mean SHBG levels 
were significantly higher in week 12 compared with 
baseline. 
In females, the mean concentrations of FSH and LH in 
week 12 compared with baseline show variable results 
(not shown). Total and free T remained stable in female 
patients, whereas the mean concentration of SHBG was 
significantly increased. 
Discussion 
This is the largest prospective study on the pharmacokinetic 
properties of mitotane published so far. Despite the expected 
difference in cumulative dose at12weeks, neither the plasma 
concentrations of mitotane nor the time to reach a therapeutic 
level differed significantly between the two starting dose 
regimens. Area under the mitotane plasma concentration/ 
time curvewaslarger in the high-dose starting group, but this 
was not statistically significant. Also, the proportion of patients 
achieving the target plasma concentration within 12 
weeks was higher in the high-dose group (10 of 20 vs 4 of 12, 
respectively). The beneficial effect of the high-dose schedule 
on mitotane exposure was stronger in a subgroup of patients 
not receiving chemotherapy. 
Reaching the target concentration of 14 mg/L or greater 
is a major goal during mitotane treatment and has been associated 
with better response both in advanced diseaseandin 
adjuvantsetting (4–6, 18).Consequently,itseemsimportant 
to reach such concentrations as early as possible to rapidly 
establish antiproliferative efficacy, although this reasoning is 
not underpinned by clinical data. 
In a previous study with 13 patients taking mitotane as 
first-line therapy, a correlation was observed between 
plasma levels and cumulative dose of mitotane (4). This sug- 
gests dose proportionality, which means that drug elimination 
is independent of the concentration present in the body 
(zero order reaction) rather than dependent (first order reaction). 
Therefore,wespeculate that in clinical practice elimination 
of mitotane proceeds at a constant rate independent 
of the plasma concentration. This is supported by the stable 
levels ofDDAthat were observed after 4 weeks of treatment 
in both groups. Consequently, administration of higher 
doses should result in higher plasma levels in a shorter period 
of time. Because steady-state levels of mitotane had not been 
reached at week 12, it is tempting to speculate that a longer 
study duration would have demonstrated that high-dose mitotane 
reaches steady-state conditions earlier. 
Our data confirm previous observations that the increase 
in plasma concentrations is in general slow and highly variable. 
Obviously this behavior cannot be sufficiently explained 
by differences in dosing only, indicating that other 
factors contribute to this observation. Potential explanations 
are related to effects on enzyme induction by concomitant 
drugs and differences in intestinal absorption, which may 
also be affected by ingested food. Also, recent data show that 
individual genetic differences are significantly associated 
with mitotane levels (19) like this is known for other drugs 
(20, 21). In the absence of baseline predictors, early measurements 
constitute the only signal whether a given patient 
hasahigh probability of reaching the therapeutic level in time 
(13). 
The observation that the high-dose schedule results in 
higher exposure in patients not receiving concomitant chemotherapy 
may be explained by multiple factors. It is possible 
that patients do not tolerate high mitotane doses in 
addition to chemotherapy or that physicians anticipate on 
the addition of chemotherapy by lowering the mitotane dosage. 
However, cumulative doses were not different among 
these subgroups. Of note, treatment compliance could be a 
limitation in this respect. Also, the administration of cytotoxic 
chemotherapy could result in lower plasma levels due 
to drug interactions or impaired intestinal uptake (22). 
No significant difference was detected between the two 
groups regarding the frequency and severity of adverse 
events. This suggests that actual dosage is not the key determinant 
of adverse effects. Of note, we did not observe any 
(significant) correlation between adverse events and mitotane 
plasma level. However, it has to be acknowledged that 
18 patients (45%) never reached a plasma level above 14 
mg/L, and only six patients had measurements above 20 
mg/L. Nevertheless, in our personal experience,AEscan usually 
be managed by adequate support, even when given in 
parallel to cytotoxic chemotherapy. An increase of GGT is 
well known and appeared in 100% of our patients. Observations 
in patients treated adjuvantly demonstrated that this 
is reversible (15, 23). 
Mitotane can induce hormonal effects soon after the onset 
of treatment. After 12 weeks a significant decrease in FT4 
was detectable with a trend for a negative correlation between 
mitotane and FT4 levels. TSH and FT3 remained unchanged 
or were increased. It is known from previous research 
that mitotane use can lead to biochemical findings 
mimicking central hypothyroidism, ie, low FT4 with approximately 
normal FT3 and TSH levels (15). Previously 
proposed explanations are a direct effect on the pituitary 
level, the induction of thyroid hormone metabolism, an increase 
in TBG levels, or changes in the thyroid hormone receptor’s 
affinity for FT4 (22, 24, 25). Also, interference with 
FT3, FT4, and/or TSH assays cannot be excluded. 
Data on the influence of mitotane on sex hormones are 
scarce. In vitro studies showed that mitotane increases the 
synthesis of steroid binding protein (26, 27). In our study, 
SHBG was markedly increased, whereas in males free T was 
decreased and LH was increased. Mitotane has been shown 
to bind the human estrogen receptor-_ with weak affinity, 
approximately 1000-fold weaker than that of estradiol itself 
(28). Although the concentration of mitotane in plasma is 
about 5.0_105 times higher than estradiol levels in men, the 
presence of increased levels of LH makes a strong estrogenic 
effect of mitotane at the pituitary level not likely. A recent 
study demonstrated significantly decreased levels of dihydrotestosterone 
in mitotane-treated patients, which might be 
the reason for the increase of gonadotrophins (29). Another 
possibility is mitotane-induced inhibition of T secretion, set 
off at least partially by an increase inSHBGand by decreased 
production (30). 
We acknowledge the limitations of our study. First, patients 
were not randomized to a dosing regimen, which could 
have introduced bias. However, due to theembedmentof the 
study within the FIRM-ACT protocol, a second randomization 
was judged to be not feasible. Second, protocol deviations 
produced missing data, which made the study underpowered 
in several analyses. Furthermore, we acknowledge 
that more patients in the high-dose group had to be excluded 
from the pharmacokinetic analyses. However, as mentioned 
in Results, the reasons for exclusion are unlikely treatment 
related, and therefore, we do not expect that this fact influenced 
the conclusions.Afourth limitation is that steady-state 
levels of mitotane were not reached in all patients. However, 
due to the aggressiveness of the disease, a longer, comprehensive 
pharmacokinetic study would be very challenging 
for patients and investigators. Finally, the study was underpowered 
to assess differences in subgroups. 
In conclusion, the high-dose starting regimen led to higher 
mitotane plasma levels within 12 weeks of treatment, and 
more patients reached the target level of 14 mg/L. Observed 
differences were greater in the subgroup of patients who did 
not receive concomitant cytotoxic chemotherapy, but the 
results were not statistically significant due to lack of power. 
The rate of AEs was similar between both groups, leading us 
to conclude that the high-dose approach is the preferred 
strategy in patients with mitotane monotherapy. However, 
in patients with reduced tolerability (eg, due to concomitant 
cytotoxic chemotherapy), a less aggressive regimen might be 
reasonable. 
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